BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

Terms: = Ovarian cancer AND TP53, TRP53, 7157, ENSG00000141510, P04637, LFS1, P53
3798 results:

  • 1. Expression of human dCTP pyrophosphatase 1 (DCTPP1) and its association with cisplatin resistance characteristics in ovarian cancer.
    Wang Y; Chen X; Chen Q; Liu T; Wu Y; Huang L; Chen Y
    J Cell Mol Med; 2024 May; 28(9):e18371. PubMed ID: 38686496
    [TBL] [Abstract] [Full Text] [Related]  

  • 2. Comprehensive Analysis of Clinically Relevant Copy Number Alterations (CNAs) Using a 523-Gene Next-Generation Sequencing Panel and NxClinical Software in Solid Tumors.
    Gupta V; Vashisht V; Vashisht A; Mondal AK; Alptekin A; Singh H; Kolhe R
    Genes (Basel); 2024 Mar; 15(4):. PubMed ID: 38674331
    [TBL] [Abstract] [Full Text] [Related]  

  • 3. Uptake of Risk-Reducing Measures, Cascade Testing, and Related Challenges Among Carriers of Breast cancer-Associated Germline Pathogenic Variants in Mexico.
    Mesa-Chavez F; Chavarri-Guerra Y; Aguilar-Y-Mendez D; Becerril-Gaitan A; Vaca-Cartagena BF; Carrillo-Bedoya A; Santiesteban-González S; Aranda-Gutierrez A; Rodríguez-Faure A; Obregon-Leal D; Quintero-Beuló G; Rodriguez-Olivares JL; Miaja M; Weitzel JN; Villarreal-Garza C
    JCO Glob Oncol; 2024 Apr; 10():e2300417. PubMed ID: 38635940
    [TBL] [Abstract] [Full Text] [Related]  

  • 4. The Predictive Role of Serum Lipid Levels, p53 and ki-67, According to Molecular Subtypes in Breast cancer: A Randomized Clinical Study.
    Faur IF; Dobrescu A; Clim IA; Pasca P; Prodan-Barbulescu C; Tarta C; Neamtu AA; Brebu D; Neamtu C; Rosu M; Duta C; Clim A; Lazar G; Totolici B
    Int J Mol Sci; 2024 Mar; 25(7):. PubMed ID: 38612725
    [TBL] [Abstract] [Full Text] [Related]  

  • 5. Functional analysis and validation of oncodrive gene AP3S1 in ovarian cancer through filtering of mutation data from whole-exome sequencing.
    Kong D; Wu Y; Liu Q; Huang C; Wang T; Huang Z; Gao Y; Li Y; Guo H
    Eur J Med Res; 2024 Apr; 29(1):231. PubMed ID: 38609993
    [TBL] [Abstract] [Full Text] [Related]  

  • 6. Human epidermal growth factor receptor-2 expression and subsequent dynamic changes in patients with ovarian cancer.
    Kim YN; Chung YS; Park E; Lee ST; Lee JY
    Sci Rep; 2024 Apr; 14(1):7992. PubMed ID: 38580676
    [TBL] [Abstract] [Full Text] [Related]  

  • 7. Harmaline induces apoptosis and inhibits migration in A2780 ovarian cancer cells in vitro.
    Shariat Razavi SA; Taghdisi Khaboushan M; Jafari R; Shahini A; Ferns GA; Bahrami A
    Physiol Rep; 2024 Mar; 12(6):e15984. PubMed ID: 38531560
    [TBL] [Abstract] [Full Text] [Related]  

  • 8. CRISPR du-HITI an attractive approach to targeting Long Noncoding RNA HCP5 as inhibitory factor for proliferation of ovarian cancer cell.
    Moradi Z; Kazemi M; Jamshidi-Khalifelou R; Bahramnia V; Esfandmaz F; Rahnavard R; Moradgholi B; Piri-Gharaghie T
    Funct Integr Genomics; 2024 Mar; 24(2):61. PubMed ID: 38507114
    [TBL] [Abstract] [Full Text] [Related]  

  • 9. Systematic review of the molecular basis of hereditary breast and ovarian cancer syndrome in Brazil: the current scenario.
    de Freitas Ribeiro AA; Junior NMC; Dos Santos LL
    Eur J Med Res; 2024 Mar; 29(1):187. PubMed ID: 38504328
    [TBL] [Abstract] [Full Text] [Related]  

  • 10. Survival time prediction in patients with high-grade serous ovarian cancer based on
    He D; Zhang X; Chang Z; Liu Z; Li B
    BMC Cancer; 2024 Mar; 24(1):337. PubMed ID: 38475819
    [TBL] [Abstract] [Full Text] [Related]  

  • 11. Static magnetic field reduces cisplatin resistance via increasing apoptosis pathways and genotoxicity in cancer cell lines.
    Zafari J; Rastegar-Pouyani N; Javani Jouni F; Najjar N; Azarshin SZ; Jafarzadeh E; Abdolmaleki P; Hoseini Shirazi F
    Sci Rep; 2024 Mar; 14(1):5792. PubMed ID: 38461218
    [TBL] [Abstract] [Full Text] [Related]  

  • 12. STEAP3 Affects ovarian cancer Progression by Regulating Ferroptosis through the p53/SLC7A11 Pathway.
    Han Y; Fu L; Kong Y; Jiang C; Huang L; Zhang H
    Mediators Inflamm; 2024; 2024():4048527. PubMed ID: 38440354
    [TBL] [Abstract] [Full Text] [Related]  

  • 13. HER2-low and Overexpression in Mucinous ovarian cancer: Analysis of ASCO/CAP and ToGA Immunohistochemical Scoring.
    Han R; Madariaga A; Gonzalez-Ochoa E; Smith AC; Wang L; Lheureux S; Rouzbahman M
    Int J Gynecol Pathol; 2024 May; 43(3):275-283. PubMed ID: 38436360
    [TBL] [Abstract] [Full Text] [Related]  

  • 14. cancer Risks Associated With
    Fortuno C; Feng BJ; Carroll C; Innella G; Kohlmann W; Lázaro C; Brunet J; Feliubadaló L; Iglesias S; Menéndez M; Teulé A; Ballinger ML; Thomas DM; Campbell A; Field M; Harris M; Kirk J; Pachter N; Poplawski N; Susman R; Tucker K; Wallis M; Williams R; Cops E; Goldgar D; ; James PA; Spurdle AB
    JCO Precis Oncol; 2024 Feb; 8():e2300453. PubMed ID: 38412388
    [TBL] [Abstract] [Full Text] [Related]  

  • 15. Paraptotic Cell Death as an Unprecedented Mode of Action Observed for New Bipyridine-Silver(I) Compounds Bearing Phosphane Coligands.
    Teixeira RG; Stefanelli A; Pilon A; Warmers R; Fontrodona X; Romero I; Costa PJ; Villa de Brito MJ; Hudec X; Pirker C; Türck S; Antunes AMM; Kowol CR; Ott I; Brozovic A; Sombke A; Eckhard M; Tomaz AI; Heffeter P; Valente A
    J Med Chem; 2024 Apr; 67(8):6081-6098. PubMed ID: 38401050
    [TBL] [Abstract] [Full Text] [Related]  

  • 16. Developing Folate-Conjugated miR-34a Therapeutic for Prostate cancer: Challenges and Promises.
    Li WJ; Wang Y; Liu X; Wu S; Wang M; Turowski SG; Spernyak JA; Tracz A; Abdelaal AM; Sudarshan K; Puzanov I; Chatta G; Kasinski AL; Tang DG
    Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396800
    [TBL] [Abstract] [Full Text] [Related]  

  • 17. Complexity of the Genetic Background of Oncogenesis in ovarian cancer-Genetic Instability and Clinical Implications.
    Murawski M; Jagodziński A; Bielawska-Pohl A; Klimczak A
    Cells; 2024 Feb; 13(4):. PubMed ID: 38391958
    [TBL] [Abstract] [Full Text] [Related]  

  • 18. Immunohistochemical and molecular pattern of p53 in epithelial ovarian cancers negative for germline BRCA1/2 variants.
    Ronchi S; Facchi S; Di Lauro E; Libera L; Carnevali IW; Zefiro F; Alexandrova E; Rizzo F; Sessa F; Tibiletti MG
    Pathol Res Pract; 2024 Mar; 255():155183. PubMed ID: 38364651
    [TBL] [Abstract] [Full Text] [Related]  

  • 19. To study the expression of estrogen, progesterone receptor and p53 immunohistochemistry markers in subtyping endometrial carcinoma.
    Yadav A; Sistla A; Swain M; Gowrishankar S; Padua M; Modi T; Himabindu R; Agarwal N; Kulkarni A; Bhandari T; Vudayaraju H; Chinnababu ; Reddy VA
    Indian J Pathol Microbiol; 2024; 67(1):62-67. PubMed ID: 38358190
    [TBL] [Abstract] [Full Text] [Related]  

  • 20. CD47-a novel prognostic predicator in epithelial ovarian cancer and correlations with clinicopathological and gene mutation features.
    Luo X; Mo J; Zhang M; Huang W; Bao Y; Zou R; Yao L; Yuan L
    World J Surg Oncol; 2024 Feb; 22(1):44. PubMed ID: 38317230
    [TBL] [Abstract] [Full Text] [Related]  


    [Next]

    of 190.